RxDoctor Payments Data

Dana Planer, DO

Internal Medicine · Port Charlotte, FLNPI 1275516197

Payments from drug & device makers

$9,959in general payments, 2019–2025

Across 545 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$1K
  • GSK$864
  • Novo Nordisk$839
  • Amgen$697
  • Johnson & Johnson$530
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$9,87499%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,959 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$473,580
Medicare patients
768
Services billed
14,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$154,491
OzempicSemaglutide79$120,475
JardianceEmpagliflozin81$109,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$93,173
MounjaroTirzepatide58$68,338
OtezlaApremilast12$57,415
FarxigaDapagliflozin Propanediol51$53,651
TrulicityDulaglutide28$45,520
XareltoRivaroxaban42$44,139
ProliaDenosumab23$40,381
Repatha SureclickEvolocumab35$36,269
JanuviaSitagliptin Phosphate24$34,841
MyrbetriqMirabegron33$30,125
Nucynta ErTapentadol Hcl12$29,391
LinzessLinaclotide24$24,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,382$157,350144 claims
Boehringer IngelheimJardiance, Glyxambi$129$129,43797 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$864$123,573145 claims
Novo NordiskOzempic$839$120,47579 claims
Lilly USA, LLCMounjaro, Trulicity$442$113,85886 claims
AmgenOtezla, Prolia$697$97,79535 claims
AstraZenecaFarxiga, Breztri Aerosphere$526$62,32065 claims
AbbVieLinzess, Ubrelvy, Synthroid$1,072$55,249130 claims
Johnson & JohnsonXarelto$530$44,13942 claims
MerckJanuvia$211$34,84124 claims
Astellas Pharma US IncMyrbetriq$366$30,12533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →